Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides.
We have investigated the use of a cationic lipid preparation to enhance antisense oligonucleotide activity in human umbilical vein endothelial cells. A liposomal preparation containing the cationic lipid N-[1-(2,3-dioleyloxy)propyl]-N,N,N-trimethylammonium chloride (DOTMA) was found to increase by at least 1000-fold the potency of an antisense oligonucleotide (ISIS 1570) that hybridizes to the AUG translation initiation codon of human intercellular adhesion molecule-1. In the presence of 8 microM DOTMA, 6-15-fold more 35S-ISIS 1570 associated with cells, at oligonucleotide concentrations from 0.01 to 5 microM, than did in the absence of DOTMA. Both 35S-ISIS 1570 association with cells and antisense activity were increased as a function of DOTMA concentration and with increasing time of incubation with the cationic lipid. Fluorescein-labeled ISIS 1570 was used to assess the intracellular distribution of the oligonucleotide in the presence and absence of DOTMA. In the absence of DOTMA, the oligonucleotide localized to discrete structures in the cytoplasm of the cell, resulting in a punctate fluorescence pattern. In the presence of DOTMA, cellular fluorescence markedly increased and the oligonucleotide localized within the nucleus, as well as to discrete structures in the cytoplasm. Accumulation of the oligonucleotide in the nucleus in the presence of DOTMA was time and temperature dependent. Nuclear accumulation was inhibited by preincubation of the cells with monensin but not chloroquine, NH4Cl, nocodazole, colcemid, or brefeldin A. These data demonstrate that cationic lipids increase antisense activity by increasing the amount of oligonucleotide associated with cells and altering intracellular distribution of the oligonucleotide.
Bennett
C F
CF
Department of Molecular and Cellular Biology, ISIS Pharmaceuticals, Carlsbad, California 92008.
Chiang
M Y
MY
Chan
H
H
Shoemaker
J E
JE
Mirabelli
C K
CK
D001483:Base Sequence; D015815:Cell Adhesion Molecules / Q000187:drug effects / Q000235:genetics; D002478:Cells, Cultured; D004730:Endothelium, Vascular / Q000166:cytology / Q000187:drug effects; D015870:Gene Expression / Q000187:drug effects; D006801:Humans; D018799:Intercellular Adhesion Molecule-1; D007700:Kinetics; D008969:Molecular Sequence Data; D016376:Oligonucleotides, Antisense / Q000493:pharmacokinetics* / Q000494:pharmacology; D000644:Quaternary Ammonium Compounds / Q000494:pharmacology*; D013347:Subcellular Fractions / Q000378:metabolism; D013873:Thionucleotides / Q000493:pharmacokinetics* / Q000494:pharmacology
D015815:Cell Adhesion Molecules; D016376:Oligonucleotides, Antisense; D000644:Quaternary Ammonium Compounds; D013873:Thionucleotides; C054005:N-(1-(2,3-dioleyloxy)propyl)-N,N,N-trimethylammonium; D018799:Intercellular Adhesion Molecule-1